🇺🇸 Latanoprost/Timolol in United States
275 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 275
Most-reported reactions
- Diarrhoea — 31 reports (11.27%)
- Dizziness — 30 reports (10.91%)
- Fall — 30 reports (10.91%)
- Off Label Use — 29 reports (10.55%)
- General Physical Health Deterioration — 28 reports (10.18%)
- Nausea — 27 reports (9.82%)
- Dyspnoea — 26 reports (9.45%)
- Anaemia — 25 reports (9.09%)
- Febrile Neutropenia — 25 reports (9.09%)
- Fatigue — 24 reports (8.73%)
Other Ophthalmology approved in United States
Frequently asked questions
Is Latanoprost/Timolol approved in United States?
Latanoprost/Timolol does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Latanoprost/Timolol in United States?
Universiti Kebangsaan Malaysia Medical Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.